Microbot Medical Advances with LIBERTY® FDA Submission

Microbot Medical ( (MBOT) ) has provided an announcement.

Microbot Medical Inc. has announced its submission of a 510(k) premarket notification to the FDA for its LIBERTY® Endovascular Robotic System, following a successful clinical trial. As the world’s first single-use, fully disposable robotic system for endovascular procedures, LIBERTY® aims to revolutionize the market by reducing costs and increasing procedure efficiency. The company anticipates FDA clearance by mid-2025, with commercialization set to follow, potentially impacting over 2 million U.S. peripheral vascular procedures annually.

Find detailed analytics on MBOT stock on TipRanks’ Stock Analysis page.